Our lead compound, APX3330, an oral anticancer agent, has shown preclinical efficacy against a variety of APE1-expressing tumors. APX3330 safety has been confirmed in 10 Phase I/II human studies of non-cancer indications with more than 422 patients.
The phase I oncology study of APX 3330 is nearing completion and Apexian plans to share results at major Oncology meetings in 2019.
Apexian plans additional clinical activity on APX3330 in 2019 as outlined in the pipeline graphic below in both cancer and other diseases where the APE1/Ref-1 target is associated with the disease.
- FDA has granted clinical evaluation of APX3330 for treatment of cancer and CIPN under one IND
- Patient enrollment completed for Phase 1 study in patients with solid tumors
- Sites for CIPN and DME studies selected
- Clinical supplies for CIPN and DME studies being manufactured